All news

Novo eyes early 2027 US CagriSema launch after 21% weight loss in REDEFINE 9

ad-hoc-news · · AI-summarised by FinFlash

Novo Nordisk's CagriSema delivered 21% weight loss at week 68 in the REDEFINE 9 trial, with a possible US launch in early 2027, alongside third-quarter results that lifted the 2026 outlook. Adjusted sales and operating profit are now guided to between minus 2% and plus 2% at constant currencies, from minus 6% to zero. Reported operating profit fell 9% to DKK 23.0 billion after impairments. The shares traded at 37.11 euros at midday.

So What?

CagriSema gives Novo a next-generation obesity catalyst to pair with its Wegovy pill. Watch US regulatory timing and competition from rival drugmakers.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.